Evidence for intercellular trafficking of VP22 in living cells

Molecular Therapy

Volumn 15, Issue 2, 2007, Pages 310-319

  Lemken, Marie Luise ^a   Wolf, Claudia ^a   Wybranietz, Wolfgang A ^a   Schmidt, Ulrike ^a   Smirnow, Irina ^a   Bühring, Hans Joerg ^a   Mack, Andreas F ^b   Lauer, Ulrich M ^a   Bitzer, Michael ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; PARAFORMALDEHYDE; PROTEIN VP22;

ARTICLE; CELL MIGRATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENHANCER REGION; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; GENE CASSETTE; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; VIRAL GENE THERAPY;

ADENOVIRIDAE; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; FLOW CYTOMETRY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS; TRANSFECTION; VIRAL STRUCTURAL PROTEINS;

HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 5;

EID: 33846274601     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300013     Document Type: Article

References (40)

1. Elliott, GD and Meredith, DM (1992). The herpes simplex virus type 1 tegument protein VP22 is encoded by gene UL49. J Gen Virol 73: 723-726.
2. Elliott, G and O'Hare, P (1997). Intercellular trafficking and protein delivery by a Herpesvirus structural protein. Cell 88: 223-233.
3. Elliott, G and O'Hare, P (1999). Intercellular trafficking of VP22-GFP fusion proteins. Gene Ther 6: 149-151.
4. Aints, A, Dilber, MS and Smith, CI (1999). Intercellular spread of GFP-VP22. J Gene Med 1: 275-279.
5. Falnes, PO, Wesche, J and Olsnes, S (2001). Ability of the Tat Basic Domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria Toxin A-fragment. Biochemistry 40: 4349-4358.
6. Hakkarainen, T, Wahlfors, T, Merilainen, O, Loimas, S, Hemminki, A and Wahlfors, J (2005). VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct. J Gene Med 7: 898-907.
7. Qiu, Z, Harms, JS, Zhu, J and Splitter, GA (2004). Bovine herpesvirus tegument protein VP22 enhances thymidine kinase/ganciclovir suicide gene therapy for neuroblastomas compared to Herpes simplex virus VP22. J Virol 78: 4224-4233.
8. Ye, D, Xu, D, Singer, AU and Juliano, R (2002). Evaluation of strategies for the intracellular delivery of proteins. Pharm Res 19: 1302-1309.
9. Zavaglia, D, Lin, EH, Guidetti, M, Pluquet, O, Hainaut, P and Favrot, MC et al. (2005). Poor intercellular transport and absence of enhanced antiproliferative activity after non-viral gene transfer of VP22-P53 or P53-VP22 fusions into p53 null cell lines in vitro or in vivo. J Gene Med 7: 936-944.
10. Fang, B, Xu, B, Koch, P and Roth, JA (1998). Intercellular trafficking of VP22-GFP fusion proteins is not observed in cultured mammalian cells. Gene Ther 5: 1420-1424.
11. Brewis, N, Phelan, A, Webb, J, Drew, J, Elliott, G and O'Hare, P (2000). Evaluation of VP22 spread in tissue culture. J Virol 74: 1051-1056.
12. Aints, A, Guven, H, Gahrton, G, Smith, CI and Dilber, MS (2001). Mapping of herpes simplex virus-1 VP22 functional domains for inter- and subcellular protein targeting. Gene Ther 8: 1051-1056.
13. Cashman, SM, Sadowski, SL, Morris, DJ, Frederick, J and Kumar-Singh, R (2002). Intercellular trafficking of adenovirus-delivered HSV VP22 from the retinal pigment epithelium to the photoreceptors-implications for gene therapy. Mol Ther 6: 813-823.
14. Greco, O, Joiner, MC, Doleh, A and Scott, SD (2005). VP22-mediated intercellular transport for suicide gene therapy under oxic and hypoxic conditions. Gene Ther 12: 974-979.
15. Wybranietz, WA, Prinz, F, Spiegel, M, Schenk, A, Bitzer, M and Gregor, M et al. (1999). Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines. J Gene Med 1: 265-274.
16. Phelan, A, Elliott, G and O'Hare, P (1998). Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol 16: 440-443.
17. Roy, I, Holle, L, Song, W, Holle, E, Wagner, T and Yu, X (2002). Efficient translocation and apoptosis induction by adenovirus encoded VP22-p53 fusion protein in human tumor cells in vitro. Anticancer Res 22: 3185-3189.
18. Zender, L, Kühnel, F, Kock, R, Manns, M and Kubicka, S (2002). VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo. Cancer Gene Ther 9: 489-496.
19. Zender, L, Köck, R, Eckhard, M, Frericks, B, Gosling, T and Gebhardt, T et al. (2002). Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. Gastroenterology 123: 608-618.
20. Dilber, MS, Phelan, A, Aints, A, Mohamed, AJ, Elliott, G and Smith, CI et al. (1999). Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther 6: 12-21.
21. Kong, BH, Wang, WX, Liu, CS, Song, L, Ma, DX and Qu, X et al. (2003). Efficacy of Lentivirus-mediated and MUC1 antibody-targeted VP22-TK/GCV suicide gene therapy for ovarian cancer. In vivo 17: 153-156.
22. Zavaglia, D, Favrot, MC, Eymin, B, Tenaud, C and Coll, JL (2003). Intercellular trafficking and enhanced in vivo antitumour activity of a non-virally delivered P27-VP22 fusion protein. Gene Ther 10: 314-325.
23. Green, KL, Southgate, TD, Mulryan, K, Fairbairn, LJ, Stern, PL and Gaston, K (2006). Diffusible VP22-E2 protein kills bystander cells and offers a route for cervical cancer gene therapy. Hum Gene Ther 17: 147-157.
24. Wybranietz, WA, Gross, CD, Phelan, A, O'Hare, P, Spiegel, M and Graepler, F et al. (2001). Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene. Gene Ther 8: 1654-1664.
25. Lee, KC, Hamstra, DA, Bullarayasamudram, S, Bhojani, MS, Moffat, BA and Dornfeld, KJ et al. (2006). Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit. Gene Ther 13: 127-137.
26. Lundberg, M and Johansson, M (2001). Is VP22 nuclear homing an artifact? Nat Biotechnol 19: 713-714.
27. Roy, V, Qiao, J, Campos-Lima, P and Caruso, M (2004). Direct evidence for the absence of intercellular trafficking of VP22 fused to GFP or to the herpes simplex virus thymidine kinase. Gene Ther 12: 169-176.
28. Lundberg, M and Johansson, M (2002). Positively charged DNA-binding proteins cause apparent cell membrane translocation. Biochem Biophys Res Commun 291: 367-371.
29. Lundberg, M, Wikstrom, S and Johansson, M (2003). Cell surface adherence and endocytosis of protein transduction domains. Mol Ther 8: 143-150.
30. Richard, JP, Melikov, K, Vives, E, Ramos, C, Verbeure, B and Gait, MJ et al. (2003). Cell-penetrating peptides. J Biol Chem 278: 585-590.
31. Sheridan, PJ, Lawrie, A, Crossman, DC., Holt, CM and Newman, CM (2005). VP22-mediated intercellular transport correlates with enhanced biological activity of MybEngrailed but not (HSV-I) thymidine kinase fusion proteins in primary vascular cells following non-viral transfection. J Gene Med 7: 375-385.
32. Harms, JS, Ren, X, Oliveira, SC and Splitter, GA (2000). Distinctions between bovine herpesvirus 1 and herpes simplex virus type 1 VP22 tegument protein subcellular associations. J Virol 74: 3301-3312.
33. Oliveira, SC, Harms, JS, Afonso, RR and Splitter, GA (2001). A genetic immunization adjuvant system based on BVP22 antigen fusion. Hum Gene Ther 12: 1353-1359.
34. Lai, Z and Brady, RO (2002). Gene transfer into the central nervous system in vivo using a recombinant lentivirus vector. J Neurosci Res 67: 363-371.
35. Noguchi, H and Matsumoto, S (2006). Protein transduction technology: A novel therapeutic perspective. Acta Med Okayama 60: 1-11.
36. Leifert, JA and Whitton, JL (2003). "Translocatory proteins" and "protein transduction domains": A critical analysis of their biological effects and the underlying mechanisms. Mol Ther 8: 13-20.
37. Chartier, C, Degryse, E, Gantzer, M, Dieterle, A, Pavirani, A and Mehtali, M (1996). Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 70: 4805-4810.
38. He, TC, Zhou, S, Da Costa, LT, Yu, J, Kinzler, KW and Vogelstein, B (1998). A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509-2514.
39. Graham, FL and Prevec, L (1995). Methods for construction of adenovirus vectors. Mol Biotechnol 3: 207-220.
40. Zhang, WW, Koch, PE and Roth, JA (1995). Detection of wild-type contamination in a recombinant adenoviral preparation by PCR. Biotechniques 18: 444-447.